This trial has been completed.

Conditions metastatic colorectal cancers, metastatic gastric cancers, metastatic oesophageal cancers, metastatic pancreatic cancers, metastatic biliary cancers, metastatic breast cancers
Treatments capecitabine, aflibercept
Phase phase 1
Target VEGF
Sponsor Jules Bordet Institute
Start date September 2013
End date October 2016
Trial size 42 participants
Trial identifier NCT01843725, 2012-005169-11, Mom1-AD12


Prospective non randomized, non-comparative, dose escalation, two arms open phase I trial to assess the safety and tolerability of capecitabine given in combination with aflibercept in patients with measurable or evaluable, chemorefractory digestive tumors or breast tumors in terms of the Maximum Tolerated Dose (MTD) and the Dose-Limiting Toxicities (DLTs), To establish the Recommended Phase II Dose (RP2D) of capecitabine in combination with Aflibercept.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
capecitabine 1100 to 1600 mg/m2/day orally in association with aflibercept 6mg/kg intravenous every 3 weeks
capecitabine Xeloda
escalation dose of capecitabine continuously
aflibercept Zaltrap
Intravenous 6mg/kg every 3 weeks
capecitabine 1700 to 2500 mg/m2/day orally 2 weeks out of 3 and aflibercept 6mg/kg intravenous every 3 weeks
aflibercept Zaltrap
Intravenous 6mg/kg every 3 weeks
capecitabine Xeloda
dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3

Primary Outcomes

To determine the maximum tolerated dose and the recommended phase II dose of capecitabine in association with aflibercept
time frame: The time point of the first toxicity evaluation would be the end of the first cycle (3 weeks)

Secondary Outcomes

The secondary endpoint is preliminary data on efficacy, and this will be evaluated using CT scan or MRI using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1
time frame: after 2 cycles (6 weeks)

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: - Histologically confirmed digestive or breast cancer that is metastatic or unresectable, for which no curative measures are possible, and chemorefractory to all known medications in the respective fields. - Age ≥ 18 years. - Life expectancy of greater than 12 weeks. - ECOG (Eastern Cooperative Oncology Group) performance status ≤ 1. - Normal organ and marrow function as defined below: - Leukocytes > 3,000/microLiter (mcL) - Hb>10g/mcL - Absolute neutrophil count > 1,500/mcL - Platelets > 100,000/mcL - Total bilirubin within 2 × institutional upper limit of normal - AST (aspartate amino transferase)/ALT (alanine amino transferase)/ALKP (Alkaline Phosphatase) levels < 5 × institutional upper limit of normal for liver metastases, < 2.5 ULN (Upper Limit of Normal) in case of no liver metastases - Creatinine within 2 × institutional upper limit of normal or creatinine clearance > 35 mL/min - Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. - Signed written informed consent (approved by an Independent Ethics Committee (IEC)) obtained prior to any study specific baseline procedures. Exclusion Criteria: - Patients with malabsorption or dysfunctional GI tract. - Participants who have had chemotherapy or radiotherapy (except limited radiotherapy for bone metastasis for instance) within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. - Participants should not receive any other experimental agents. - Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. - History of cardiovascular ischemic disease or cerebrovascular incident within the last six months, NYHA class III and IV congestive heart failure. - Intolerance to atropine sulfate or loperamide - Known dihydropyrimidine dehydrogenase deficiency - Treatment with CYP3A4 inducers unless discontinued > 7 days prior to randomization - Any of the following in 3 months prior to inclusion: grade 3-4 gastrointestinal bleeding (unless due to resected tumor), treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or diverticulitis. - Major surgery within 6 weeks. - Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Pregnant women, lactation or refusal to use adequate contraceptive measures (hormonal or barrier method of birth control, abstinence).

Additional Information

Official title Modulation of Metabolic Index in Tailoring Treatment of Incurable Metastatic ColoRectal Cancer (CRC) Program 1.
Principal investigator Alain Hendlisz, MD
Description Aflibercept has been found to be active with a broad pharmacological index against early and advanced stage disease in a variety of preclinical solid tumor models including sarcomas, and ovarian, prostate, mammary, colon, and gastric carcinomas either as a single agent or in combination with cytotoxic agents. Metronomic chemotherapy, namely administration of continuous low-dose chemotherapy at close, regular intervals, with no prolonged drug-free interruptions, bases its rationale on the fact that virtually all classes of cancer chemotherapeutic drugs are designed to damage DNA or disrupt microtubules of dividing cells. Endothelial cell division takes place during new blood vessel formation, including tumour angiogenesis. Frequent administration of most cytotoxic agents at low doses is thought to increase their putative antiangiogenic activity. This strategy lowers the toxicity and theoretically the risk of emergence of drug-resistant tumour cells compared to classic maximum tolerated dose (MTD)-based chemotherapy.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by Jules Bordet Institute.